Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis.

Abstract

We undertook a prospective, controlled study to evaluate the effect of trimethoprim-sulfamethoxazole in children with proven Escherichia coli O157:H7 enteritis on the duration fo symptoms, on fecal excretion of pathogen, and on the risk of progression to hemolytic-uremic syndrome. There was no statistically significant effect of treatment on progression of symptoms, fecal pathogen excretion, or the incidence of HUS (2/22 vs 4/25; p = 0.67). Our results suggest that a multicentric trial using rapid diagnostic methods to permit early randomization should be carried out.

• Authors: F Proulx, J P Turgeon, G Delage, L Lafleur, L Chicoine
• Journal: The Journal of pediatrics (J Pediatr) Vol. 121 Issue 2 Pg. 299-303 (Aug 1992) ISSN: 0022-3476 [Print] United States
• PMID: 1640303 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Trimethoprim, Sulfamethoxazole Drug Combination

Topics

• Child
• Child, Preschool
• Enteritis (drug therapy, microbiology)
• Escherichia coli (classification, isolation & purification)
• Escherichia coli Infections (complications, drug therapy)
• Feces (microbiology)
• Female
• Hemolytic-Uremic Syndrome (etiology)
• Humans
• Infant
• Male
• Prospective Studies
• Trimethoprim, Sulfamethoxazole Drug Combination (therapeutic use)